Nanjing Leads Biolabs
Nanjing Leads Biolabs is a China-based biotechnology company running 8 late-stage cancer trials of LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer and hepatocellular carcinoma.
Overview
Nanjing Leads Biolabs, based in Nanjing, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 8 recruiting or active phase 2 and phase 3 interventional cancer trials, testing LBL-024 and LBL-034 in triple-negative breast cancer, non-small-cell lung cancer, hepatocellular carcinoma, oesophageal cancer and multiple myeloma. The largest, NCT05170958 (A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumours), plans to enrol 396 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyShanghai AbelZeta
Shares Hepatocellular carcinoma, Multiple myeloma and the tag ctgov-sponsor.
- CompanyCatalYm
Shares Hepatocellular carcinoma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Multiple myeloma, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyBioInvent International
Shares Hepatocellular carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAP Biosciences
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyScancell
Shares Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag ctgov-sponsor.
- CompanyChongqing Precision Biotech
Shares Multiple myeloma and the tag ctgov-sponsor.
- CompanyHaihe Biopharma
Shares Ovarian cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.